Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cancer patients want financial screening early in care, study finds

2.

Novel Agent for Chronic GVHD Wins FDA Approval

3.

Formaldehyde Causes More Cancer Than Any Other Toxic Air Pollutant

4.

Recurrent UTIs impact eGFR in children with vesicoureteral reflux

5.

MGRS Relapse-Free Survival Better With Maintenance Therapy


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot